14. 慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー ［臨床試験数：145，薬物数：139（DrugBank：23），標的遺伝子数：12，標的パスウェイ数：21］
Searched query = "Chronic inflammatory demyelinating polyneuropathy", "Chronic inflammatory demyelinating poly (radiculo) neuropathy", "Multifocal motor neuropathy", "CIDP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||EUCTR2020-002438-34-DK||19/08/2020||11/06/2020||Fampridine for treatment of functional disability in patients with immune mediated polyneuropathy||Fampridine for treatment of residual neurological deficits in patients treated with immunoglobulins for chronic inflammatory demyelinating polyneuropathy||Chronic inflammatory demyelinating polyneuropathy |
MedDRA version: 20.0Level: LLTClassification code 10072650Term: CIDPSystem Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
|Trade Name: Fampyra|
Product Name: Fampyra
INN or Proposed INN: FAMPRIDINE
|Department of Neurology, Odense University Hospital||NULL||Authorised-recruitment may be ongoing or finished||Female: yes|
|2||EUCTR2015-000828-28-NL||26/07/2016||30/11/2015||Immunoglobulins given under the skin to treat patients with multifocal motor neuropathy (MMN). To increase the amount of immunoglobulins, an enzyme is added that will temporarily create more space under the skin. This space is filled with immunoglobulins. By this way less infusions should be needed.||Titlle: Subcutaneous immunoglobulins with rHuPH20 in multifocal motor neuropathy (MMN) It is an interventional cross-over study where the use of the combination of subcutaneous immunoglobulins together with the enzyme hyaluronidase (rHuPH20) is compared with the current gold standard intravenous immunoglobulins (IVIg). Non-inferiority and tolerability are studied in 20 MMN patients. The reason to add rHuPH20 is to increase volumes per infusion and in this way contribute to reduced frequency of infusions. - Hymne||Non-inferiority and safety/tolerance of Hyqvia compared to IVIg in 20 MMN patients with at least one conduction block on EMG and stable on IVIg.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]||Trade Name: Hyqvia|
Product Name: Hyqvia
|UMC Utrecht||NULL||Authorised-recruitment may be ongoing or finished||Female: yes|
|3||NCT02111590||January 2014||9/4/2014||Immunoglobulin Dosage and Administration Form in CIDP and MMN||The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN||Chronic Inflammatory Demyelinating Polyneuropathy;Multifocal Motor Neuropathy;Hemolytic Anemia||Drug: Immunoglobulins||Rigshospitalet, Denmark||Aarhus University Hospital;Octapharma Pharmazeutika Produktionsges.m.b.H.||Completed||18 Years||80 Years||Both||36||N/A||Denmark|
|4||EUCTR2007-000710-37-IT||04/10/2007||12/02/2008||A multicentre study of subcutaneous immunoglobulin in patients with Multifocal Motor Neuropathy (MMN) - ND||A multicentre study of subcutaneous immunoglobulin in patients with Multifocal Motor Neuropathy (MMN) - ND||Maintenance treatment with subcutaneous immunoglobulin (Vivaglobin) in patients with MMN. |
MedDRA version: 9.1Level: LLTClassification code 10036105Term: Polyneuropathy
|Trade Name: Vivaglobin|
INN or Proposed INN: Immunoglobulins, normal human, for extravascular adm.
|CSL Behring AG||NULL||Not Recruiting||Female: yes|
|5||EUCTR2005-001136-76-IT||09/07/2007||07/09/2007||Double blind Randomized Controlled trial of prolonged treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)with high dose intravenous immunoglobulins (IVIg) or intravenous metilprednisolone (IVMP). A phase III study. - IVIg CIDP||Double blind Randomized Controlled trial of prolonged treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)with high dose intravenous immunoglobulins (IVIg) or intravenous metilprednisolone (IVMP). A phase III study. - IVIg CIDP||Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) |
MedDRA version: 14.1Level: PTClassification code 10057645Term: Chronic inflammatory demyelinating polyradiculoneuropathySystem Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
|Trade Name: IGVENA*FL 200ML 10G+SET|
INN or Proposed INN: Immunoglobulins, normal human, for intravascular adm.
|KEDRION||NULL||Not Recruiting||Female: yes|